



Drug Prior Authorization Committee Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
March 17, 2022	10:00am – 3:00pm (CST)	Department of Natural Resources 1101 Riverside Dr, Jefferson City, MO 65101 and WebEx

[* Click HERE for Meeting Documents *](#)

Committee Members Present:

Conrad Balcer, DO, Chair
J.K. Sturgeon, PharmD, BCPS
Laura Kingsley, PharmD
Matthew Stinson, MD
Maya Moody, DO, FAAP
Morgan Sperry, PharmD

Committee Members Absent:

Angeline Stanislaus, MD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Elizabeth Sissom, RN, Clinical Management
Nikki Ashley, Pharmacy Program Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Ambra Stotler, CPhT, Benefit Program Senior
Specialist

Contractors Present:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP, Conduent
Jennifer Colozza, PharmD, Conduent
Ashleigh Holeman, PharmD, Conduent
Megan Fast, PharmD, Conduent
Serena Barden, PharmD, BCPS, Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Valerie Schmitz, RN, BSN, Wipro
Ashley Lytton, RN, BSN, Wipro

Others Present:

Anabelle Keohane
Andrew Royer
Audrey Rattan
Bill G
Brian Strickland
Camille Kerr
Chris Brown
Cindi Pearson
David Hershey
Dave Miley
Desiree Owen
Donald Nopper
Elaine Siegfried
Erin Hohman
Folger Tuggle
GCampbell
Jackie Adamec
Jenny
Jessica Petrie
Jim Maxson
Joshua McNeil
Karen Floeder
Karen Powell
Katie
Keith Gulley
Kenneth Berry
Kurt Hendrickson
Larry Palmisano
Laurie Krekemyer
Lila Kertz
Lisa Tracz
Melissa Basil

Michele Shirley
Mike Chen
Nishil Patel
Nolan
Rebecca Abt
Robert Groeneveld
Robert Pearce
Sandy
Sean Jones
Selena Gonzalez
Steven Angelcyk
Suzanne Hensley
Trisha Ladyman
Vince

<p>Welcome, Announcements and Introductions</p>	<p>Conrad Balcer, Committee Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with Nikki Ashley, MHD's new Pharmacy Program Specialist. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p> <p>Morgan Sperry also introduced her DIC fellow, Rebecca Abt, PharmD.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the December meeting.</p> <p>Decision: The Committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short, Joshua Moore and Angela Wilson presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July-Feb 2022 Eligibles by Group - July-Feb 2022 Expenditures by Enrollment Group - July-Feb 2022 Expenditures by Service - FY22 Pharmacy Spend vs July-Feb 2022 Total Medicaid Spend - July 2021 – March 2022 Pharmacy Expenditures - Pharmacy Program Top 4 Drug Classes per FY - Hep C FY 2018 – FYTD 2022 - Mavyret Expenditures July 2019 – March 2022 - Synagis Expenditures FY2019 – FYTD2022 - FY2019 – FYTD2022 Rare Disease Expenditures Per Day - Additional discussions arose around: <ul style="list-style-type: none"> o The pharmacy spend goals and budget along with comparisons between the other state Medicaid programs. o New initiatives and streamlining older edits to help to decrease prior authorization, fax and call volumes to the helpdesk and overall enhanced workflow for all those involved. o Process of backdating in the expansion population. o June DPAC meeting consisting of only clinical and fiscal edits due to the PDL vendor RFP process. PDL edit reviews are expected to resume at the September DPAC meeting.

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Committee for discussion and action. - Questions arose around the liquid formulations for the new drugs and their availability to children. It was explained that these liquid formulations are expected to follow the general rule MHD has set forth that allows children 10 and younger to receive the liquid without a step through the solid dosage formulation. - Questions arose around the dosing limitations for Injectafer and if those would apply across the board to all Injectafer strengths. It was explained that each strength has its own dosage limits and the one presented today only applies to the 1,000mg vial. - No public comment provided. <p>Decision: The Committee voted to accept the presented new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review	
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Committee which included: <ul style="list-style-type: none"> o Imcivree Clinical Edit o Megestrol Clinical Edit o Nulibry Clinical Edit o Oxervate Clinical Edit o Oxlumo Clinical Edit o Spravato Clinical Edit o Zokinvy Clinical Edit o Zulresso Clinical Edit - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
Acne or Rosacea, Select Topical Agents Step Therapy Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Questions arose on the Erygel removal from the edit – it was explained that the cost has decreased significantly resulting in its removal. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
C5 Complement Inhibitors Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Fabry Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Givlaari Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Isturisa Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Scenesse Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Questions arose on the expected population we would see – it was explained with this being a rare disease that it is very difficult to predict the expected population. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Sickle Cell Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Public comment provided by: <ul style="list-style-type: none"> o Susie Moroney with Novartis on Adakveo yielded time back. o Lisa Tracz with Global Blood Therapeutics (GBT) on Oxbryta. - The Committee asked what GBT would recommend as clinical check points/outcomes that MHD could utilize for continuation of therapy approval criteria. <ul style="list-style-type: none"> o The Committee was deferred to the MSL to answer that question and would be asked to attend DUR to follow up. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Systemic Antifungals Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Tavneos Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Larry Palmisano with Chemocentryx <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Voxzogo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

Preferred Drug List Edit Review

Preferred Drug Edits With No Annual Changes

Discussion:

- Joshua Moore introduced the edits for discussion to the Committee which included:
 - o Actinic Keratosis Agents, Topical
 - o Androgenic Agents
 - o Antibiotics, Inhaled
 - o Antifungals, Oral
 - o Antifungals, Topical
 - o Antihistamines & Antihistamines/Decongestant Combinations, 2nd Generation
 - o Antihistamines, Intranasal
 - o Antivirals, Herpes Oral
 - o Antivirals, Topical
 - o Benzoyl Peroxide/Antibiotic Combinations
 - o Corticosteroids, Oral Inhaled
 - o Corticosteroids, Topical
 - o Corticosteroids and Rhinitis Agents, Intranasal
 - o Cough/Cold Preparations
 - o Epinephrine Agents, Self-Injectable
 - o Fluoroquinolones, Ophthalmic
 - o Fluoroquinolones, Otic
 - o Glaucoma Agents
 - o Mast Cell Stabilizers, Ophthalmic
 - o NSAIDs, Ophthalmic
 - o Psoriasis Agents, Oral
 - o Psoriasis Agents, Topical
 - o Retinoids, Topical
 - o Ulcerative Colitis Agents, Oral
 - o Ulcerative Colitis Agents, Rectal
- Public comment provided by:
 - o Dave Miley with Teva
 - o Erin Hohman with AbbVie on Durysta and Lumigan (Glaucoma Agents PDL) yielded time back.

	<ul style="list-style-type: none"> - Questions arose from the Committee on the Antifungals, Oral PDL <ul style="list-style-type: none"> o It was discussed that the NPD L griseofulvin tablets were must safer in pediatrics and teens compared to the PDL terbinafine tabs which also has many PA steps. o Many providers are utilizing the griseofulvin suspension to bypass the terbinafine PA criteria which ALT/AST might not apply to the pediatric population as they generally have good functioning livers. o MHD to research more and bring back to the Committee as the cost between the medications greatly differs. - Antifungals, Topical <ul style="list-style-type: none"> o Nystatin ointments are flagging as non-preferred at the pharmacy – MHD to research and bring back to the Committee. - Benzoyl Peroxide/Antibiotic Combinations <ul style="list-style-type: none"> o Questions arose around single ingredient benzoyl peroxide being covered by MHD. Providers may prefer to start participants on the individual 5-10% benzoyl peroxide products instead of a combination agent. MHD to research and bring back to the Committee. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Asthma Policy Updates</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the recommended updates to MHD’s Asthma Policy. - See Beta Adrenergic Agents, Nebulized; Beta Adrenergic Agents, Short Acting; and Leukotriene Receptor Modifiers PDL edits for decisions on the recommendations. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Beta Adrenergic Agents, Nebulized</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p style="text-align: center;">Beta Adrenergic Agents, Short Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Discussion arose around: <ul style="list-style-type: none"> o Concerns with participants at risk not receiving appropriate therapy, especially in the pediatric population. o Operationalization at point of sale <ul style="list-style-type: none"> ▪ Helping pharmacies ensure participants receive what they need and educate them appropriately on when the next refills can be dispensed ▪ Soft vs hard edits ▪ DUR messages back to the pharmacies o Provider education - After discussion, the following criteria change was proposed <ul style="list-style-type: none"> o Cumulative quantity exceeds: <ul style="list-style-type: none"> ▪ 3 inhalers per 180 days for participants aged ≥ 18 years - Public comment provided by: <ul style="list-style-type: none"> o Dave Miley with Teva <p>Decision: The Committee voted to accept the recommended criteria with the additional revisions above in blue.</p>
<p style="text-align: center;">Leukotriene Receptor Modifiers</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Anticholinergics, Long Acting Inhaled</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticholinergics, Short Acting and Combinations Inhaled</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Anticholinergics, LABA Combinations</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antihistamines, Ophthalmic</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Antiparasitics, Topical</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Atopic Dermatitis Agents, Immunomodulators</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Beta Adrenergic Agents, Long Acting</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Corticosteroids, Ophthalmic Soft</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Discussion on the trial and failure definition - Public comment provided by: <ul style="list-style-type: none"> o Desiree Owen with Kala Pharmaceuticals on Eysuvis yielded time back o Andrew Royer with Eyecare-Partners on Eysuvis <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Hepatitis C Agents</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Erin Hohman with AbbVie on Mavyret yielded time back <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Pancreatic Enzymes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Erin Hohman with AbbVie on Creon yielded time back <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p style="text-align: center;">Respiratory Monoclonal Antibodies</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Lila Kertz with Cardinal Glennon Children’s Hospital on Dupixent o Elaine Siegfried with Cardinal Glennon Children’s Hospital on Dupixent o Nishil Patel with Amgen on Tezpire <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p style="text-align: center;">Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and June 2022 meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
<p style="text-align: center;">Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 1st Quarter 2022 (July, August, September) - Top 25 Drugs by Paid Number 1st Quarter 2022 (July, August, September) - Call Center User Statistics November 2021 - CyberAccess Logging Information - New Drug Statistics November 2021
<p style="text-align: center;">Adjournment</p>	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person and WebEx) on Thursday, June 16, 2022.</p>

NEXT MEETING: Thursday, June 16, 2022
615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for March 17, 2022							
	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
December 2021 Minutes	Y	Y	SY	Y	MY	Y	Y
New Drug Review	Y	SY	Y	Y	MY	Y	Y
Clinical & Fiscal Edits With No Annual Changes	Y	Y	Y	A	MY	SY	Y
Acne or Rosacea, Select Topical Agents Clinical Edit	Y	SY	MY	A	Y	Y	Y
C5 Complement Inhibitors Clinical Edit	Y	MY	Y	A	SY	Y	Y
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit	Y	Y	Y	A	MY	SY	Y
Fabry Disease Clinical Edit	Y	SY	MY	A	Y	Y	Y
Givlaari Clinical Edit	Y	Y	SY	A	MY	Y	Y
Isturisa Clinical Edit	Y	Y	Y	A	MY	SY	Y
Scenesse Clinical Edit	Y	MY	SY	A	Y	Y	Y
Sickle Cell Disease Clinical Edit	Y	Y	Y	A	MY	Y	SY
Systemic Antifungals Clinical Edit	Y	SY	MY	A	Y	Y	Y
Tavneos Clinical Edit	Y	Y	Y	A	MY	SY	Y

Drug Prior Authorization Committee Meeting – March 17, 2021
Approved June 16, 2022

Roll Call for March 17, 2022							
	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Voxzogo Clinical Edit	Y	Y	Y	A	MY	Y	SY
Preferred Drug Edits With No Annual Changes	Y	Y	MY	A	SY	Y	Y
Beta Adrenergic Agents, Nebulized	Y	Y	SY	A	MY	Y	Y
Beta Adrenergic Agents, Short Acting	N	Y	Y	A	SY	Y	MY
Leukotriene Receptor Modifiers	Y	MY	SY	A	Y	Y	Y
Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors	Y	Y	Y	A	MY	SY	Y
Anticholinergics, Long Acting Inhaled	Y	SY	Y	A	MY	Y	Y
Anticholinergics, Short Acting and Combinations Inhaled	Y	Y	Y	A	MY	SY	Y
Anticholinergics, LABA Combinations	Y	SY	MY	A	Y	Y	Y
Antihistamines, Ophthalmic	Y	Y	Y	A	MY	Y	SY
Antiparasitics, Topical	Y	MY	Y	A	Y	Y	SY
Atopic Dermatitis Agents, Immunomodulators	Y	Y	MY	A	Y	Y	SY
Beta Adrenergic Agents, Long Acting	Y	SY	Y	A	MY	Y	Y

Drug Prior Authorization Committee Meeting – March 17, 2021
Approved June 16, 2022

Roll Call for March 17, 2022							
	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Corticosteroids, Ophthalmic Soft	Y	Y	Y	A	Y	SY	MY
Hepatitis C Agents PDL Edit	Y	SY	Y	A	MY	Y	Y
Pancreatic Enzymes	Y	Y	Y	A	MY	Y	SY
Respiratory Monoclonal Antibodies	Y	Y	Y	A	Y	SY	MY
Motion to Close	Y	Y	MY	A	SY	Y	Y
Adjournment	Y	SY	Y	A	MY	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain